HMPL A83
Alternative Names: HMPL-A83Latest Information Update: 03 Apr 2023
At a glance
- Originator HUTCHMED
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 31 Dec 2022 HUTCHMED has patents pending for HMPL 283 in China, USA, Europe, Japan, Argentina and Taiwan
- 18 Jul 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV)
- 18 Jul 2022 Pharmacodynamics data from a preclinical studies in Solid tumours and Haematological malignancies released by HUCTHMED